



REINSURANCE **HOT NEWS**

October 4, 2024

Addition of the following 2 Drugs to High-Cost Specialty Drug (BIO) Reinsurance coverage

AHCCCS Financial Review Committee has approved the following Drugs for High-Cost Specialty Drug Reinsurance effective 10/01/2024:

Vimzin - for the treatment of Morquio syndrome.

Strensiq - for treatment of childhood hypophosphatasia.

